ClinicalTrials.gg
RecruitingNCT04103671Updated Mar 30, 2023

Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR

An interventional study of Prompt panretinal photocoagulation and 25G Pars-plana vitrectomy in Non Proliferative Diabetic Retinopathy, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-30.

Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University — 7 open to participants now, 7 under way, none of them phase 3. Diabetic Retinopathy · Zhongshan Ophthalmic Center, Sun Yat-sen University.

Started
2019
the only one that year
No phase
4 of 10
3 open now
Registered
2nd of 10
by date

Among the 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University, this one is the only one that started in 2019, is one of 4 with no phase, and was the 2nd registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

7 of the 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Diabetic Retinopathy by Zhongshan Ophthalmic Center, Sun Yat-sen University, or all of them as a file.
02

Study summary

It is estimated that there are about 600 million diabetes mellitus (DM) patients all over the world until 2040,and almost 50% of whom have some degree of diabetic retinopathy (DR) at any given time. About 5% to 10% diabetic retinopathy would develop vision-threatening complications, including proliferative diabetic retinopathy (PDR), capillary non-perfusion, or macular edema. Data from the DRS suggest that given long enough duration of diabetes, approximately 60% of patients with DR will develop PDR, and without intervention, 75% nonproliferative diabetic retinopathy (NPDR) will development PDR within 1 year follow up, 45% will develop high-risk PDR, nearly half of PDR will experience profound visual loss. panretinal photocoagulation (PRP) only reduced 50% risk of sever visual loss and about 25% of the sNPDR patients who finished PRP need Pars-plana vitrectomy (PPV) in a 5 year follow up.

Vitreous have been proven to play an important role in the development of NPDR to PDR, which were the collection of vascular endothelial growth factor (VEGF) factors and the major component of proliferative lesion in the later stage of PDR.

Micro-invasive Pars-plana vitrectomy has been shown as a safe and effective method in the treatment of PDR, through removing the pathological vitreous, proliferative membrane and also the VEGF factors. However, whether or not Micro-invasive Pars-plana vitrectomy will be more effective than PRP to control the progression of NDPR remained unknown.

03

Conditions studied

  • Non Proliferative Diabetic Retinopathy

Browse trials for

Keywords

  • NPDR
  • Pars-plana vitrectomy
  • panretinal photocoagulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years, male or female
  2. Type 1 or type 2 diabetes
  3. Presence of severe NPDR according to the diagnosis of 4-2-1 rule,

    One or more of the following, in the absence of PDR:

    • More than 20 intraretinal hemorrhages in each of four quadrants
    • Definite venous beading in two or more quadrants
    • Prominent intraretinal microvascular abnormality (IRMA) in one or more quadrants
  4. Best corrected Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity letter score > 24 (approximate Snellen equivalent 20/320) on the day of randomization.
  5. Media clarity, pupillary dilation, and study participant cooperation sufficient to administer PRP and obtain adequate fundus photographs and optical coherence tomography (OCT).
  6. Able and willing to provide

Exclusion criteria

Exclusion Criteria:

  1. Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant
  2. In the opinion of the investigator, A condition that would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
  3. Participation in an trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied.
  4. Blood pressure > 180/110 (systolic above 180 or diastolic above 110).

    *If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.

  5. Myocardial infarction, other acute cardiac event requiring hospitalization, stroke, , or treatment for acute congestive heart failure within 4 months prior to randomization
  6. Systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization

    * These drugs should not be used during the study

  7. For women of : pregnant or lactating or intending to become pregnant within the next 3 years.

    * Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed

  8. History of prior panretinal photocoagulation (prior PRP is defined as ≥100 burns outside of the posterior pole
  9. If macular edema is present, it is considered to be primarily due to a cause other than diabetic macular edema.
  10. An ocular condition is present (other than diabetic retinopathy) that, in the opinion of the investigator, might alter visual acuity during the course of the study (e.g., retinal vein or artery occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.).
  11. Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye were otherwise normal).
  12. History of intravitreal anti-VEGF treatment at any time in the past 2 months
  13. History of treatment (intravitreal or peribulbar) at any time in the past 4 months.
  14. History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 4 months or anticipated within the next 6 months following randomization.
  15. History of laser capsulotomy performed within 2 months prior to randomization
  16. Aphakia.
  17. Uncontrolled glaucoma (in investigator's judgment).
  18. Exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or substantial blepharitis.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
272 participants (estimated)

Study arms

  • Experimental
    Group A

    Prompt panretinal photocoagulation

    Procedure: Prompt panretinal photocoagulation

  • Experimental
    Group B

    Micro-invasive Pars-plana vitrectomy

    Procedure: 25G Pars-plana vitrectomy

Interventions

  • ProcedurePrompt panretinal photocoagulation

    Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation

  • Procedure25G Pars-plana vitrectomy

    Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid. Surgery should be completed within 4 weeks after randomization.

06

What researchers measure

Primary outcomes

  1. progression rate of severe non proliferative diabetic retinopathy

    the number of patients with severe non proliferative diabetic retinopathy progressed to proliferative diabetic retinopathy in each group from the baseline to 12 months

    Time frame: 12 months

Secondary outcomes

  1. the change of best corrected visual acuity

    The mean change in best corrected visual acuity in each group from baseline to 12 months

    Time frame: 12 months

  2. the rate of re-treatment

    The number of patients who need re-treatment including supplement laser or vitrectomy from baseline to 12 months

    Time frame: 12 months

  3. The occurrence of diabetic macular edema

    The occurrence number of diabetic macular edema in each group from baseline to 12 months

    Time frame: 12 months

  4. The change of central retinal thickness

    the change of central retinal thickness from baseline to 12 months

    Time frame: 12 months

  5. The change of visual field

    the change of visual field from baseline to 12 months

    Time frame: 12 months

  6. The occurrence of cataract

    the occurrence of cataract from baseline to 12 months

    Time frame: 12 months

  7. The change of quality of life

    the change of quality of life as assessed by questionnaire at 12 months

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zheng W, Chen S, Ding X, Lai K, Xiao S, Lin Y, Liu B, Jin L, Li J, Wu Y, Ma Y, Lu L, Liu Y, Li T. Microinvasive pars plana vitrectomy versus panretinal photocoagulation in the treatment of severe non-proliferative diabetic retinopathy (the VIP study): study protocol for a randomised controlled trial. BMJ Open. 2021 Feb 22;11(2):e043371. doi: 10.1136/bmjopen-2020-043371. PubMed 33619191 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Dec 2024, 60 months after the start.

Of 111 non-industry interventional studies with no phase under Diabetic Retinopathy, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's planned 60 months is above that.

Counting every sponsor, half of 126 studies reached it within 29 months; a quarter within 11 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2019
First posted
Sep 25, 2019
StartActual
Dec 4, 2019
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Mar 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04103671
Responsible party
Sponsor
First posted
Sep 25, 2019
Start date
Dec 4, 2019
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Mar 30, 2023

Study contacts

tao li, Dr
Contact
litao2@mail.sysu.edu.cn
66683995 ext. +8620
shida chen, Dr
Contact
chenshd3@mail.sysu.edu.cn
66610721 ext. +8620

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion